hengrui glp-1 China's Hengrui/Kailera duo just filed an NDA for HRS9531: a dual GLP‑1/GIP agonist designed for long-term obesity treatment (not just diabetes). This strategy sets it apart from other GLP‑1 drugs. What makes Hengrui has submitted an IND

g , Left, percent of cell number from Slc33a1 -knockout KP cells expressing a vector control or SLC33A1 cDNA treated with DMSO or tunicamycin for 4 days under indicated concentrations

Preclinical studies in rodent models have consistently demonstrated that GLP-1 agonists decrease alcohol consumption, reduce alcohol-seeking behavior, and prevent relapse-like drinking after periods of abstinence

Graf & Kastin, 1984)

Es un suplemento lquido diseado para apoyar la quema de grasa y aumentar la energa durante los entrenamientos

Dipeptidyl peptidase IV DPP-IV, also known as CD26, is a serine protease that degrades both GLP-1 and GLP-2